PROGNOSIS OF STRATEGY IN THERAPY OF GASTROESOPHAGEAL REFLUX DISEASE

摘要

The prognosis of the strategy in the therapy of gastroesophageal reflux disease comprises the analysis of the questionnaire of the general criteria of the response to the treatment of the acid-dependant diseases of the gastro-intestinal tract. The patients with the consistent daily complaints of the heartburn without any anxious symptoms are advised the trial course of the therapy using Pantoprasol at a dose of 40 mg twice a day after the meals. The significant decrease of the heartburn for three days is indicative non-erosion type of the gastroesophageal reflux disease with the probability of 90%. Then the treatment with Pantoprasol continues without endoscopic examination at a dose of 40 mg twice a day after the meals for 4 weeks or longer if necessary. When the trial treatment is not effective for 5-7 days, the erosive form of the gastroesophageal reflux disease is suggested. In such cases, Pantoprasol is prescribed at a dose of 40 mg twice a day after the meals for 8 weeks. After the treatment, the control endoscopy is performed. When the erosion of the esophagus is healed, the treatment with Pantoprasol continues depending on the clinical state of the patient.